<div id="readability-page-1"><p>In a report released yesterday, Sebastian Sandler from J.P. Morgan reiterated a Buy rating on Adaptive Biotechnologies, with a price target of <span id="expert-recommendation-target">$20.00</span>. The company’s shares closed yesterday at $15.69.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul>  <p>In addition to J.P. Morgan, Adaptive Biotechnologies also received a Buy from William Blair’s Andrew Brackmann in a report issued yesterday. However, on December 1, Morgan Stanley maintained a Hold rating on Adaptive Biotechnologies (NASDAQ: ADPT).</p></div>

ADPT

<p>J.P. Morgan's Sebastian Sandler reiterated a Buy rating for Adaptive Biotechnologies (ADPT) with a $20 price target, while shares closed at $15.69. William Blair also issued a Buy rating, but Morgan Stanley maintained a Hold rating on December 1.</p>

Adaptive Biotechnologies (ADPT) Receives a Buy from J.P. Morgan